Blueprint Medicines Corporation (BPMC) had a good day on the market for Friday December 06 as shares jumped 5.26% to close at $78.48. About 435,480 shares traded hands on 7,236 trades for the day, compared with an average daily volume of n/a shares out of a total float of 49.2 million. After opening the trading day at $74.84, shares of Blueprint Medicines Corporation stayed within a range of $78.71 to $74.07.
With today’s gains, Blueprint Medicines Corporation now has a market cap of $3.86 billion. Shares of Blueprint Medicines Corporation have been trading within a range of $102.98 and $44.58 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Blueprint Medicines Corporation is based out of Cambridge, MA and has some 320 employees. Its CEO is Jeffrey W. Albers.
